Case Series of Small Cell Lung Cancer Transformation
as Resistance Mechanism to Epidermal Growth Factor
Receptor-Tyrosine Kinase Inhibitor

QR Code

Case Series of Small Cell Lung Cancer Transformation as Resistance Mechanism to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor

Bibliographic Details
Main Authors:	Liam, C, Chai, C.
Format:	Article
Language:	English
Published:	Elsevier Inc. 2017
Subjects:	R Medicine (General)
Online Access:	http://ir.unimas.my/id/eprint/19180/ http://ir.unimas.my/id/eprint/19180/1/Case%20Series%20of%20Small%20Cell%20Lung%20Cancer.pdf

Similar Items

Case series of small cell lung cancer transformation post tyrosine kinase inhibitor failure
by: Chai, C.S., et al.
Published: (2017)

Resistance mechanisms causing first-line epidermal growth factor receptor-tyrosine kinase inhibitor treatment failure
by: Chai, C.S., et al.
Published: (2017)

An investigation into the effects of the epidermal growth factor receptor tyrosine kinase inhibitor "Gefitinib" on human breast cancer
by: Gutteridge, Eleanor
Published: (2010)

EGFR-directed tyrosine kinase inhibitors for non-small cell lung cancer
by: Fatin Nur Elyana Mohd Sidek,, et al.
Published: (2025)

Outcome of patients with advanced lung adenocarcinoma treated with first-line epidermal growth factor receptor tyrosine kinase inhibitors versus cytotoxic chemotherapy
by: Chai, Chee She
Published: (2015)

Small Cell Transformation and T790M Mutation as Coresistance Mechanisms for First-line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy Failure
by: Chee, Shee Chai
Published: (2017)

Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant?
by: Hamdi, Amir Imran Faisal, et al.
Published: (2022)

Benzalhydantoin derivative-based inhibitors of eight receptor tyrosine kinases: synthesis, in-vitro, and in-silico study
by: Muhammad Naufal,, et al.
Published: (2025)

A prospective study on epidermal growth factor receptor mutations in non-small cell lung cancer in Malaysian patients
by: Liam, C K, et al.
Published: (2012)

Effects of 4 multitargeted receptor tyrosine kinase inhibitors on regional hemodynamics in conscious, freely moving rats
by: Carter, Joanne J., et al.
Published: (2016)

Linifanib – a multi-targeted receptor tyrosine kinase inhibitor and a low molecular weight gelator
by: Marlow, Maria, et al.
Published: (2015)

Self-assembling tyrosine kinase inhibitors for localised targeted delivery
by: Al-Ameedee, Mohammed
Published: (2017)

Epidermal Growth Factor Receptor Mutation in Newly Diagnosed Lung Adenocarcinoma
by: Chee, Shee Chai, et al.
Published: (2017)

Epidermal growth factor receptor mutations in non- small cell lung cancers in a multiethnic Malaysian patient population
by: Liam, Chong-Kin, et al.
Published: (2014)

An apoferritin-based drug delivery system for the tyrosine kinase inhibitor gefitinib
by: Kuruppu, Anchala I., et al.
Published: (2015)

Real-time analysis of the binding of fluorescent VEGF₁₆₅a to VEGFR2 in living cells: Effect of receptor tyrosine kinase inhibitors and fate of internalized agonist-receptor complexes
by: Kilpatrick, Laura E., et al.
Published: (2017)

Characteristics of epidermal growth factor receptor (EGFR)-Mutated Non Small Cell Lung Carcinoma (NSCLC)-patients who developed resistance to first or second generation Egfrtyrosine Kinase Inhibitor (TKI) Therapy through T790M mutation / Vijayan Munusamy
by: Vijayan, Munusamy
Published: (2017)

Determination of gene expression of tyrosine kinase receptors (HER family) in FFPE tissue of colorectal adenocarcinoma
by: Othman @ Jaffar, Rosfayati, et al.
Published: (2015)

Detection of epidermal growth factor receptor mutations in formalin fixed paraffin embedded biopsies in Malaysian non-small cell lung cancer patients
by: Ng, Tiffany Shi Yeen, et al.
Published: (2013)

Spectroscopic and molecular modeling studies on the interaction of tyrosine kinase inhibitors with human serum albumin / Md. Zahirul Kabir
by: Md. Zahirul , Kabir
Published: (2018)

Effects of receptor tyrosine kinase inhibitors on VEGF165a- and VEGF165b-stimulated gene transcription in HEK-293 cells expressing human VEGFR2
by: Carter, Joanne J., et al.
Published: (2015)

Epidermal growth factor receptormutations in lung adenocarcinoma in Malaysian patients
by: Liam, Chong Kin, et al.
Published: (2013)

Mapping 18F-fluorodeoxyglucose metabolism using PET/CT for the assessment of treatment response in non-small cell lung cancer patients undergoing epidermal growth factor receptor inhibitor treatment: a single-centre experience
by: Suppiah, Subapriya, et al.
Published: (2017)

Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules
by: Yu, Yu, et al.
Published: (2015)

Roles of Rho-associated kinase in lung cancer review
by: Zakaria, Muhammad Asyaari, et al.
Published: (2020)

Inhibition of transforming growth factor-β via the activin receptor-like kinase-5 inhibitor attenuates pulmonary fibrosis
by: Koh, Rhun Yian, et al.
Published: (2015)

Survival rate and prognostic factors of survival among chronic myeloid leukaemia adults after initiation of tyrosine kinase inhibitor therapy in Hospital Ampang, Selangor
by: Ali, Zakiah Bakar
Published: (2024)

Biological significance of human epidermal growth factor receptor 2 (HER2) in breast cancer: effect of oestrogen receptor
by: Ahmad, Dena Akram Jerjees
Published: (2016)

Targeting the hypoxic expression of epidermal growth factor receptor
by: Alamoudi, Abdulmohsin
Published: (2021)

The focal adhesion kinase Pyk2 links Ca2+ signalling to Src family kinase activation and protein tyrosine phosphorylation in thrombin-stimulated platelets
by: Canobbio, I., et al.
Published: (2015)

Evaluation of transcriptional cyclin dependent kinase inhibitors as potential cancer therapeutics
by: Liu, Xiangrui
Published: (2012)

The proline-rich tyrosine kinase Pyk2 regulates platelet integrin aIIbß3 outside-in signaling
by: Cipolla, L., et al.
Published: (2013)

Translational control of epidermal growth factor receptor in neurodegenerative diseases
by: Smalley, Daniel. S.
Published: (2017)

Role of Focal Adhesion Tyrosine Kinases in GPVI-Dependent Platelet Activation and Reactive Oxygen Species Formation
by: Carrim, N., et al.
Published: (2014)

A phase 2 trial of decreasing tyrosine kinase inhibitor dose in chronic myeloid leukaemia patients with stable major molecular response: data from the British DESTINY study
by: Clark, Richard E., et al.
Published: (2017)

Anti-tumor activity of metformin in human epidermal growth factor receptor 2 positive breast cancer cells
by: Huda, Fathul, et al.
Published: (2021)

A randomized control trial comparing peginterferon-α-2a versus observation after stopping tyrosine kinase inhibitor in chronic myeloid leukemia with deep molecular response for at least two years
by: Kuan, Jew-Win, et al.
Published: (2016)

Impaired thrombin-induced platelet activation and thrombus formation in mice lacking the Ca2+-dependent tyrosine kinase Pyk2
by: Canobbio, I., et al.
Published: (2013)

Approved and experimental small-molecule oncology kinase inhibitor drugs: a mid-2016 overview
by: Fischer, Peter M.
Published: (2017)

Src family tyrosine kinase Lyn mediates VWF GPIb-IX induced platelet activation via the cGMP signaling pathway
by: Yin, H., et al.
Published: (2008)